Fujifilm Enters Growing Market of Vaccine Contract Manufacturing
![](/46/pdcnewsitem/03/38/18/AUYdvN6jFmg81C6.png)
Fujifilm Corporation has announced an agreement to acquire Kalon Biotherapeutics, a biopharmaceutical CMO having expertise in vaccine manufacturing, and will enter the vaccine CMO market to expand its biopharmaceutical business.
On 22 October 2014, Fujifilm Diosynth Biotechnologies — a Fujifilm subsidiary — signed an Interest Purchase Agreement, with the owners of Kalon. At the initial closing of this transaction expected to occur within the next few months, FDBU will acquire 49% of the total membership interests in Kalon and will be entitled to appoint a majority of Kalon’s board members. Thereafter, FDBU may increase its interest share up to 100% based on achievement of certain milestones set forth in the Interest Purchase Agreement.
Kalon is a biopharmaceutical CMO with advanced technologies and facilities and is a key subcontractor to one of the three Centers For Innovation In Advanced Development and Manufacturing (CIADM) awarded by the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture medical countermeasures to protect public health in emergencies, including incidents of bioterrorism or an outbreak of pandemic influenza. The state of Texas, through the Texas Emerging Technology Fund, provided funding critical to the development and support of this center.
Kalon’s strength is in manufacturing vaccines using the technique of mammalian cell culture. It employs world class technologies for robust, high containment manufacturing, which completely contains the viruses used to manufacture vaccines inside production suites, thereby enabling safe, stable manufacture of vaccines to be used as public medical countermeasures against threats such as pandemic influenza, Ebola and Anthrax. In addition, Kalon utilises state-of-the-art mobile clean rooms (MCRs) featuring high containment, compactness and mobility. Up to twenty MCRs can be installed at the National Center for Therapeutics Manufacturing facility operated by Kalon. The MCRs enable concurrent manufacturing of several types of vaccines. Moreover, the ability to easily expand the number of MCRs allows for prompt response to increasing capacity demands.
These MCRs are suitable not only for cell-cultured vaccines, but also for all kinds of biopharmaceuticals, including antibodies, and meet the growing demand for high-variety low-volume manufacturing.
Fujifilm entered biopharmaceutical CMO business by acquiring FDBU and Fujifilm Diosynth Biotechnologies UK Limited from Merck & Co., Inc in 2011 and has been expanding its businesses through the partnership with Mitsubishi Corporation, who has extensive experiences in the pharmaceutical business.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance